Health Condition 1: null- Mild to moderate symmetrical stable plaque psoriasis
Conditions
Interventions
Intervention1: Cyclosporin A Liposomal gel: 1.00% w/w, 1.50% w/w, 2.00% w/w, 2.50% w/w,
OD, topical for 8 weeks
Intervention2: Cyclosporin A: Liposomal gel
Intervention3: Cyclosporin A Lecithin organo
Sponsors
UGC Center with Potential for Excellence in Biomedical Sciences
Eligibility
Inclusion criteria
Inclusion criteria: • Adults of both sexes, regardless of color or social class; • Age 12 or older, with good mental health; • Patients of stable plaque psoriasis with bilaterally symmetrical plaques measuring • Patients who is registered at the psoriasis clinic of the dermatology outpatient department; • Patients who agree to participate and sign the Informed Consent and • Patients who agree to return for follow-up visits.
Exclusion criteria
Exclusion criteria: • Patients with impaired kidney function, uncontrolled hypertension, past or present malignancy, infection, pregnancy and lactation, primary or secondary immunodeficiency, and known hypersensitivity to drug or its ingredients; • Patients who received any systemic, immunosuppressive or phototherapy at least 4 weeks or taken any topical antipsoriatic treatment within preceding two weeks prior to the study; • Patient under the treatment with drugs which have known pharmacological interaction with CysA; • Patients who also have psoriatic plaques of skin disorders caused by fungi or bacteria and who are making use of antimycotics or antibiotics and • Patients who do not agree to the terms described in the informed consent Informed Consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Four point scale Dermatological Sum Score (DSS)Timepoint: 0, 2, 4, 6, 8 | — |
Secondary
| Measure | Time frame |
|---|---|
| Seven point Physicians Global Evaluation (PGE)Timepoint: 0, 2, 4, 6, 8 | — |
Countries
India
Contacts
Public ContactDr O P Katare
Postgraduate Institute of Medical Education & Research
Outcome results
None listed